HMG-CoA reductase inhibitor pharmacogenomics: overview and implications for practice

Area of Science:

• Pharmacogenomics
• Cardiovascular Medicine
• Biochemistry

Background:

• HMG-CoA reductase inhibitors (statins) are primary treatments for hypercholesterolemia and coronary heart disease.
• Significant interpatient variability exists in statin-induced lipid reduction.
• Factors beyond initial cholesterol levels and dosing, such as genetics, may explain response differences.

Purpose of the Study:

• To review the role of genetic polymorphisms in influencing patient responses to statin therapy.
• To identify specific genes and pathways where polymorphisms might affect lipid-lowering efficacy.

Main Methods:

• Literature review of studies investigating genetic polymorphisms and statin response.
• Analysis of polymorphisms in genes related to drug metabolism, transport, cholesterol biosynthesis, and lipid metabolism.

Main Results:

• Genetic polymorphisms in various genes can significantly alter lipid responses to statins.
• Variations in genes encoding drug metabolizing enzymes, transporters, and lipid pathway proteins are implicated.
• These genetic factors contribute to the observed interindividual variability in statin efficacy.

Conclusions:

• Genetic polymorphisms are a key determinant of interpatient variability in statin response.
• Understanding these genetic factors could lead to personalized statin therapy.
• Further research into pharmacogenomics can optimize hyperlipidemia treatment strategies.